PKI-587 stin and may be new candidate

and may be new candidate for glima treatment in the clinic

white blood count

24 hours) decreases cell number from 50 µg/ml and is notably decreased at 75 µg/ml

cyclin B1/cdk1

3-d]pyrimidin-4-yl) piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxylate

PKI-587 stin and may be new candidatePKI 587is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, PI3K mTOR kinase inhibitor PKI 587 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival,